ORAL THIN FILMS MARKET ANALYSIS

Oral Thin Films Market, By Product (Sublingual Film and Fast Dissolving Dental/Buccal Film), By Disease Indication (Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In October 2022, IntelGenxCorp, oral drug delivery company declared that it has been granted a U.S. FDA Food and Drug Administration Generic Drug User Fee Act ("GDUFA") for its Buprenorphine Buccal Film. The opioid Belbuca, which is used to treat severe continuous pain, has a generic equivalent called buprenorphine buccal film that can be administered over an extended period of time.
In August 2022, the U.S. Food and Drug Administration (FDA) awarded Libervant (diazepam) Buccal Film to Aquestive Therapeutics for the acute management of sporadic, stereotypical episodes of frequent seizure activity.
In November 2021, CURE Pharmaceutical Holding Corporation, pharmaceutical company obtained patent approval from the United States Patent and Trademark Office (USPTO) for its CUREfilm Blue Technology, an oral soluble film containing sildenafil citrate
In September 2021, Aquestive Therapeutics, pharmaceutical company and IntelGenx Corp. oral drug delivery company established a collaborative agreement for the co-development and commercialization of oral films containing Tadalafil for the treatment of erectile dysfunction within the U.S.